Sobi awarded Company of the Year at the European Mediscience Awards 2014

Stockholm, Sweden, July 1, 2014 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) has been awarded the Company of the Year Award at the European Mediscience Awards 2014. The Company of the Year Award is awarded to a company who has gained recognition from analysts and investors for management, financial stability, and growth with a well-defined strategy to deliver its key financial, ethical and social ambitions.

"Sobi is truly honoured to be recognised by the Mediscience community", says Geoffrey McDonough, President and CEO of Sobi.

The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe. The event recognises the importance of the capital markets to fund growth and innovation. The awards celebrate, amongst others, the breakthrough of the year, the best technology and the most significant contribution to the industry.

All the winners are presented here:


About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with two late stage biological development projects within Haemophilia. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at

For more information please contact
Media relations Investor relations
Oskar Bosson Jörgen Winroth
Head of Communications Vice President, Head of Investor Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506

Mediscience Company of the Year Award


Source:Swedish Orphan Biovitrum AB(publ)